Description: Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
Home Page: biostage.com
84 October Hill Road
Holliston,
MA
01746
United States
Phone:
774 233 7300
Officers
| Name | Title |
|---|---|
| Mr. David Green | CEO & Chairman |
| Mr. Yu Hong | Pres |
| Dr. William L. Fodor Ph.D. | Chief Scientific Officer |
| Mr. Joseph L. Damasio Jr. | Chief Financial Officer |
| Dr. Shunfu Hu Ph.D. | VP of Bus. Devel. & Operations |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 28.4738 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |